HCV-Target: Hepatitis C Therapeutic Registry And Research Network-A Longitudinal, Observational Study


The purpose of this study is to collect and study information on patients with chronic Hepatitis C Virus (HCV) who are being treated with the protease inhibitors (telaprevir and boceprevir) that have recently been approved by the FDA. This study investigates if and how drugs affect certain types of patients differently; compares length of HCV treatment in different groups of patients; compares ways to manage drug side effects; identifies genetic reasons as to why certain people react differently to study drugs.


hepatitis c virus, protease inhibitors, telaprevir, boceprevir, side effects

Principal Investigator

David R Nelson, M.D.



Contact Information



Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams